Rockwell Medical Inc  

(Public, NASDAQ:RMTI)   Watch this stock  
Find more results for RMTI
6.20
-0.23 (-3.58%)
After Hours: 6.20 0.00 (0.00%)
Aug 17, 4:53PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.15 - 6.49
52 week 3.55 - 8.98
Open 6.38
Vol / Avg. 155,798.00/161,218.00
Mkt cap 320.79M
P/E     -
Div/yield     -
EPS -0.42
Shares 51.74M
Beta 2.04
Inst. own 32%
Nov 6, 2017
Q3 2017 Rockwell Medical Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 9, 2017
Q2 2017 Rockwell Medical Inc Earnings Call - Webcast
Aug 9, 2017
Q2 2017 Rockwell Medical Inc Earnings Release
Jun 1, 2017
Rockwell Medical Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -53.48% -37.16%
Operating margin -50.73% -37.93%
EBITD margin - -36.50%
Return on average assets -37.90% -23.16%
Return on average equity -60.16% -34.36%
Employees 300 -
CDP Score - -

Address

30142 S Wixom Rd
WIXOM, MI 48393-3440
United States - Map
+1-248-9609009 (Phone)
+1-248-9609119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company's drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

Officers and directors

Robert L. Chioini Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Thomas E. Klema CPA, MBA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 61
Bio & Compensation  - Reuters
Ajay Gupta M.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Raymond D. Pratt M.D. Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
David Domzalski Director
Bio & Compensation  - Reuters
Robin L. Smith M.D. Director
Age: 51
Bio & Compensation  - Reuters
Patrick J. Bagley Independent Director
Age: 68
Bio & Compensation  - Reuters
Ronald D. Boyd Independent Director
Age: 52
Bio & Compensation  - Reuters